Evidence map›Paper›PMID 34978050›Full record

ArticleJournal of nephrology2022

Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.

Cristian Ionita, Daniele Marcelli, Cristian Nita, Carmen Anton, Suzana Berca, Smaranda Vacar, Oana Schiller, Carmen Gheorghiu, Claudia Barth

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. COVID-19 Vaccination in Hemodialysis Patients Correspondence.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Cristian Ionita *B. Braun Avitum Romania, 11-15 Tipografilor street, S-Park, B3 building, 2nd floor, Bucharest, Romania.
Daniele Marcelli *Medical Scientific Affairs B. Braun Avitum, Schwarzenberger Weg 73-79, Melsungen, Germany. daniele.marcelli@bbraun.com.ORCID http://orcid.org/0000-0002-7650-8578
Cristian NitaRCC Avitum Cluj-Napoca, 15 Tabacarilor Street, Cluj-Napoca, Romania.
Carmen AntonRCC Avitum Suceava, 19 Universitatii Street, Suceava, Romania.
Suzana BercaRCC Avitum Targu Jiu, 116 Unirii Street, Targu Jiu, Romania.
Smaranda VacarRCC Avitum Targu Mures, 1 Soarelui Street, Sângeorgiu de Mures, Romania.
Oana SchillerRCC Avitum Timisoara, 28 Gheorghe Ranetti Street, Timisoara, Romania.
Carmen GheorghiuB. Braun Avitum Romania, 11-15 Tipografilor street, S-Park, B3 building, 2nd floor, Bucharest, Romania.
Claudia BarthMedical Scientific Affairs B. Braun Avitum, Schwarzenberger Weg 73-79, Melsungen, Germany.
B. Braun (Germany) · DECamera de Comerț Industrie și Agricultură Timișoara · ROŞtefan cel Mare University of Suceava · ROTechnical University of Cluj-Napoca · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn hemodialysis patients, coronavirus disease 2019 is associated with high morbidity and mortality. Aim of the study was to evaluate the antibody level against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients treated with two different mRNA-based vaccines, in a multicenter survey. PATIENTS AND

methodsSince April 2020, in the 5 participating Centers, periodic screening of all patients with PCR testing has been performed every 2 weeks. The study included two cohorts of patients on maintenance hemodialysis treated with the BNT162b2 or with the mRNA-1273 Covid-19 vaccine. The tests for antibodies against the receptor-binding domain was performed by the anti-SARS-CoV-2 S enzyme immunoassay (Roche Elecsys).

resultsOf the 398 included patients, 303 received the BNT162b2 and 95 the mRNA-1273 vaccine. In patients without previous infection, the median levels of anti-S antibodies were 297 U/mL and 1,032 U/mL for those treated with BNT162b2 or mRNA-1273, respectively (p < 0.001). In patients with previous infection, the median levels of SARS-CoV-2 anti-S antibodies were 7,516 U/mL and 17,495 U/mL for those treated with BNT162b2 or mRNA-1273, respectively (p = 0.005). The Charlson comorbidity index (CCI) was significantly associated with protective levels of anti-spike IgG, with 3.6% of low- or non-responders having a CCI of 2-4 versus 18.9% in those with a CCI of 8 or more. The adjusted OR of developing a sufficient antibody level between the two vaccines was 3.91 (p = 0.0766) in favor of mRNA-1273.

conclusionsBoth of the evaluated mRNA-based vaccines for SARS-CoV-2 showed good efficacy. Preliminary data may data suggest a  higher antibody response to the mRNA-1273 vaccine.

Indexed as

COVID-19COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273Antibody FormationBNT162 VaccineHumansRenal DialysisRNA, MessengerSARS-CoV-22019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesRNA, MessengerHemodialysis patientsHumoral responsemRNA-based SARS-Cov-2 vaccineSARS-Cov-2 vaccination

Identifiers

PMID34978050
PMCPMC8720556
OpenAlexW4206430492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.